Preventive cytoprotection in social diseases
- 作者: Skotnikov AS1, Gorokhovskaya GN1, Shilov AM1, Yun VL1, Khamurzova MA1
-
隶属关系:
- 期: 卷 87, 编号 8 (2015)
- 页面: 29-43
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.08.2015
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31790
- ID: 31790
如何引用文章
全文:
详细
Among many cytoprotective drugs, only a few of them that have a targeted metabolic effect include agents that partially inhibit oxidation of free fatty acids, the so-called p-FOX inhibitors (partial fatty acid oxidation inhibitors). Aim. To develop a procedure for the preventive use of meldonium dihydrate in day-hospital patients with comorbidity. Subjects and methods. The investigation enrolled 189 patients (116 men and 73 women; mean age, 55.9±4.4 years) who were followed up for initial manifestations of cardiovascular and/or another somatic disease and were at high risk for unfavorable cardio- and cerebrovascular events, as well as complications of emergency alcohol-related conditions. The investigation of the efficacy and safety of meldonium dihydrate was planned as an open-label clinical trial in three parallel groups different in the directivity patterns of potential complications («Cardio», «Cerebro», «Alco»). The drug’s dosage averaged 500 to 1000 mg/day. Results. The day-hospital use of meldonium dihydrate demonstrated high safety profile and a positive role in the prevention of cardio- and cerebrovascular catastrophes and complications of emergency alcohol-related conditions and chronic alcoholic visceropathy, leading to delayed dyslipidemia progression, diminished insulin resistance, improved blood rheological properties, and suppressed chronic systemic inflammation and also proving its role in the prevention of renal vascular injury and toxic (ethanol) encephalopathy. Meldonium therapy showed positive effects in delaying the progression of dyslipidemia, diminishing insulin resistance, improving blood rheological properties, and suppressing chronic systemic inflammation and also proved its role in preventing renal vascular injury and toxic (ethanol) encephalopathy, which confirmed the versatility of the cytoprotective effect of meldonium. Conclusion. The drug has proved to be effective and safe in hemodynamic, electrolytic, hepatic, and other parameters, which makes it expedient to include meldonium in the day-hospital formulary of drugs for a preventive parenteral cycle according to the developed regimen (a 10-day cycle at least 1—2 times a year) for patients at high risk for social diseases and their complications.
参考
- Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians’ perspective. Heart Fail Rev. 2002;7(2):187-203. doi: 10.1023/a:1015384710373.
- Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(8):634-641. doi: 10.1016/j.ehj.2004.02.018.
- van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac bum-out syndrome? Cardiovasc Res. 2004;61(2):218-226. doi: 10.1016/j.cardiores.2003.11.014.
- Pilz S. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography. Eur Heart J. 2007;28(22):2763-2769. doi: 10.1093/eurheartj/ehm343.
- Men T. Russian mortality trends for 1991—2001: analysis by cause and region. BMJ. 2003;327(7421):964. doi: 10.1136/bmj.327.7421.964.
- Laine H, Katoh C, Luotolahti M. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999;100(24):2425-2430. doi: 10.1161/01.cir.100.24.2425.
- Opie LH. Mechanisms of cardiac contraction and relaxation. Braunwald’s heart disease: a textbook of cardiovascular medicine. Ed. Zipes D., Libby P., Bonow R.O., Braunwald E. Pensylvania: Elsevier Saunders; 2005:457-490.
- Konhilas JP, Leinwand LA. Partnering up for cardiac hypertrophy. Circ Res. 2006;98(8):985-987 and Comment Circ Res. 2006;98(8):1089-1097.
- Бадаева С.В. Факторы риска гипертрофии миокарда при хронической болезни почек. Нефрология и диализ. 2008;2:94-104.
- Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail. 2009;2:556-562.
- Асташкин Е.И. Коррекция энергетического обмена в миокарде — новое направление в лечении сердечно-сосудистых заболеваний. Сердце и метаболизм. 2008;21:1-3.
- Schulze PC. Myocardial lipid accumulation and lipotoxicity in heart failure. J Lipid Res. 2009;50:2137-2138.
- Edgar D, Shabalina I, Camara Y, Wredenberg A, Calvaruso MA, Nijtmans L, Nedergaard J, Cannon B, Larsson NG, Trifunovic A. Random point mutations with major effects on protein-coding genes are the driving force behind premature aging in mtDNA mutator mice. Cell Metab. 2009;10(2):131-138.
- Lango R, Smolenski RT, Narkiewicz M. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001;51(1):21-29.
- Siliprandi N, Di Lisa F, Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther. 1991;5(Suppl. 1):17-24.
- Szwed H, Sadowski Z, Pachocki R. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II) TRIMetazidine in POLand. Eur Heart J. 2001;22:2267-2274.
- Makolkin V, Osadchiy K. Trimetazidine modified release in the treatment of stable angina. TRIUMPH Study. Clin Drug Invest. 2004;24(12):731-738.
- Шилов А.М. Место препаратов с метаболической направленностью в лечении ишемических синдромов. Фарматека. 2013;13:81-86.
- Schofield RS, Hill JA. The use of ranolazine in cardiovascular disease. Expert Opin Investig Drugs. 2002;11(1):117-123.
- Wolff AA. The MARISA investigators and CV therapeutics. MARISA: Monotherapy Assessment of Ranolazine in Stable Angina. J Amer Coll Cardiology. 2000;35(Suppl. A):408.
- Chaitman BR, Pepine CJ, Parker JO. Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309-316.
- Chaitman BR, Skettino SL, Parker JO. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Amer Coll Cardiology. 2004;43(8): 1375-1382.
- Scirica BM, Morrow DA, Hod H. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non—ST-Segment—Elevation Acute Coronary Syndrome. Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non—ST-Elevation Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation. 2007;116:1647-1652.
- Lopaschuk GD, Wall SR, Olley PM. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chainacylcarnitine. Circ Res. 1988;63(6):1036-1043.
- Turcani M., Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation. 1997;96(10): 3681-3686.
- Hanaki Y., Sugiyama S., Ozawa T. Effect of 3-(2,2,2-trimelhylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol — induced mitochondrial dysfunction. Res Commun Chem Phatol Pharmacol. 1999;64:157-160.
- Dzerve V, Matisone D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Sem Cardiovasc Med. 2010;16(3):1-8.
- Dzerve V, MILSS I Study Group. A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial «MILSS I». Medicina (Kaunas). 2011;47(10):544-551.
- Дзерве В. Результаты исследования MILSS II. Квітень. 2010;7:236.
- Михин В.П., Чернятина М.А., Панченко Г.В., Харченко А.В. Эффективность мельдония в составе комплексной терапии острого коронарного синдрома. Кардиология. 2014;11:11-19.
- Гордеев И.Г., Бекчиу Е.А., Люсов В.А. Оценка влияния миокардиальных цитопротекторов на процессы перекисного окисления липидов у больных со стабильной стенокардией до и после хирургической реваскуляризации миокарда. Российский кардиологический журнал. 2005;3:18-22.
- Калвиньш И.Я. Новые патогенетические факторы развития и подходы к лечению атеросклероза. Кардиоваскулярная терапия и профилактика. 2013;5:87-90.
补充文件
![](/img/style/loading.gif)